Therapeutic effects of probiotic Clostridium butyricum WZ001 on bacterial vaginosis in mice

Abstract

Aims To observe the therapeutic effects of vaginal infusion of probiotic Clostridium butyricum WZ001 on bacterial vaginosis (BV) in mice. Methods and Results Female ICR mice were used to establish the model of BV by infecting oestrogen‐treated mice with Escherichia coli, and then treated with high‐ and low dose of C. butyricum. Clinical indexes of mice in the C. butyricum‐treated groups were significantly improved and comparable to those in the antibiotic group. Pap staining showed that neutrophil count was significantly increased after modelling and largely decreased after C. butyricum treatment (P < 0·01). Dynamic observation of E. coli and Lactobacillus showed that the number of E. coli significantly decreased in the C. butyricum‐treated groups or in the antibiotic group with prolonged treatment (P < 0·01). Besides, the number of E. coli in the low‐dose C. butyricum group was higher than that in either its high‐dose counterpart or the antibiotic group respectively (P < 0·01). The number of Lactobacillus decreased evidently in the antibiotic group (P < 0·01), while that in the C. butyricum groups remained consistent. Moreover, C. butyricum inhibited the proliferation of E. coli by the experiment in vitro. The phosphorylation of nuclear factor‐kappa B (NF‐κB) p65 in vaginal tissue and the serum levels of inflammatory cytokines, IL‐1β, TNF‐α and IL‐6, increased after modelling and significantly decreased after treated with C. butyricum (P < 0·01), with no difference found when compared with the antibiotic group. Conclusion Clostridium butyricum inhibits the growth of pathogenic bacteria as well as the inflammatory response induced by E. coli and promotes the growth of Lactobacillus to maintain the vaginal micro‐ecological balance. Significance and Impact of the Study Our results suggest that probiobitc C. butyricum WZ001 has a great potential in the clinical treatment of BV.

Therapeutic, Prophylactic, and Functional Use of Probiotics: A Current Perspective

“…Such preventive effects were based on different actions, such as amelioration of inflammatory cytokines, retard sialidase enzyme activity, and reduced G. vaginalis binding capacity to vaginal epithelial cells. In addition, in a recent test on mice, probiotic Clostridium butyricum WZ001 strain not only suppressed the growth of G. vaginalis and decreased inflammatory cytokines but also improved the lactobacilli growth to normalize the vaginal microecological balance ( Zhou et al, 2019 ). A meta-analysis of probiotics-based RCTs for VB treatment reported that currently combo treatments strategies, i.e., probiotics plus antibiotics, are more effective than single applications of both.…”

Synthetic bacterial consortia transplantation for the treatment of Gardnerella vaginalis-induced bacterial vaginosis in mice

“…Other reports also displayed that probiotics can inhibit the growth of G. vaginalis in vitro [ 39 ]. Lactic acid may also directly affect host tissues by modulating the immune system and gene expression [ 49 ]. In the present study, the administration of SCBT and VMT reduced the number of G. vaginalis detected in the vagina.…”

Multi-Omics Analysis After Vaginal Administration of Bacteroides fragilis in Chickens

“…Specific Clostridium has the potential to synthesize antibacterial compounds (Pahalagedara et al, 2020). Zhou et al (2019a) found that Clostridium butyricum WZ001 inhibited inflammation induced by E. coli and maintained vaginal microecological balance in mice. In addition, Romboutsia had the highest proportion in the B. fragilis group.…”